Decoy Therapeutics Inc DCOY

Decoy Therapeutics outlined a plan to pursue a pan-filovirus D-MAV program via the FDA Animal Rule, backed by non-dilutive funding through government grants and partnerships. Building on earlier pan-coronavirus activity, the company uses its IMP³ACT engine to design filovirus fusion inhibitors. In vitro data show a first-generation candidate against Ebola Zaire with IC50 of 1.56 μM and cross-activity against Marburg at 1.04 μM, marking multi-virus potency and improvement over the pan-coronavirus lead and remdesivir. The goal is a single broad-spectrum pan-filovirus D-MAV for pre- and post-exposure prophylaxis against Ebola Zaire, Marburg, Sudan, and Bundibugyo. The program emphasizes extended tissue residence and potentially weekly dosing, with PRV eligibility and non-dilutive monetization through government channels. Decoy's broader biodefense pipeline includes MERS and endemic coronaviruses. Strategic move to pursue FDA Animal Rule development and non-dilutive funding could materially affect financing and timelines for a broad-spectrum pan-filovirus program.

Decoy Therapeutics signs a warrant inducement agreement with an existing institutional investor to exercise 1,184,434 Series B Milestone Warrants for about $3.85 million gross proceeds at $3.25 per share. In exchange, the investor will receive new unregistered warrants to buy up to 2,368,868 shares at $3.25, exercisable after stockholder approval and expiring five years later. The exercise of existing warrants also reduces the exercise prices of Series A and Series C warrants to $3.25. Closing is expected around Sept. 23, 2026. Proceeds will fund working capital and general corporate purposes. The private placement is conducted under Section 4(a)(2) with Curvature Securities as sole placement agent, and registration for resale of new shares will be filed with the SEC. The release includes standard forward-looking statements and risk disclosures. Provides about $3.85M gross proceeds and issues new warrants, boosting liquidity but diluting shareholders.

Decoy Therapeutics announced a refined strategy to develop its Designable Multi-Antivirals (D-MAVs) against filoviruses, pursuing a pan-filovirus program under the FDA Animal Rule pathway and seeking non-dilutive funding. In vitro tests showed potent activity of a first-generation de novo D-MAV candidate against Ebola Zaire and cross-family activity against Marburg; the program aims to cover Ebola Zaire, Sudan, Bundibugyo, and Marburg with a single, broad-spectrum prophylactic. The company’s IMP³ACT AI/ML engine is used to design peptides with extended tissue residence time and longer half-lives, enabling potentially weekly dosing. If successful, filovirus approvals could qualify for FDA Tropical Disease Priority Review Vouchers, providing a potential $100–$180 million non-dilutive monetization opportunity. Decoy plans to fund its filovirus and MERS programs through government grants and partnerships, and to leverage the Animal Rule to accelerate regulatory timelines and SNS procurement. Non-dilutive funding opportunities via FDA Animal Rule and potential PRV monetization could materially shift financing and regulatory timelines for DCOY.

Decoy Therapeutics Inc (DCOY) expanded its intellectual property portfolio covering designable multi-antivirals and the IMP³ACT™ platform. IP expansion directly bolsters protection of core antiviral tech and platform, strengthening competitive position and future prospects.

Decoy Therapeutics reports breakthrough in vitro activity against Ebola Zaire, expanding its D-MAV platform into high consequence global health threats. Platform expansion to Ebola via positive in vitro data signals major strategic progress that can shift company trajectory and investor sentiment.

DCOY stock nearly doubled in value today on a major rally whose drivers remain unspecified. Sudden doubling of market value signals a major positive catalyst likely to shift valuation and sentiment.

Decoy Therapeutics, Inc. announces up to $21 million private placement financing. Up to $21 million private placement provides key funding to advance Decoy Therapeutics operations and initiatives.

Decoy Therapeutics partners with hVIVO to advance lead D-MAV™ candidate into clinical trials. Partnership advances lead candidate to clinic, marking major development step for Decoy Therapeutics.

Decoy Therapeutics Inc (DCOY) builds momentum with accelerating execution, entering a highly catalytic phase featuring a clearly defined path to clinical development of its antiviral pipeline. Clear path to clinical development of antiviral pipeline represents a major strategic advancement likely to boost investor sentiment and alter DCOY's trajectory.

Decoy Therapeutics Inc. (DCOY) regained compliance with Nasdaq's minimum bid price requirement, satisfying the $1.00 threshold for 10 consecutive trading days and avoiding delisting risk. Regaining Nasdaq compliance averts delisting and stabilizes stock liquidity and investor sentiment.

Decoy Therapeutics Inc. (DCOY) enters strategic partnership with Quantori to deploy Google Cloud-native integrated AI-driven peptide design and molecular simulation platform. Strategic AI partnership accelerates peptide drug discovery and enhances technological edge in biotech R&D.

Decoy Therapeutics Inc (DCOY) announced a 1-for-12 reverse stock split. The 1-for-12 reverse split seeks to raise share price for listing compliance, moderately influencing market sentiment and short-term performance.

Decoy Therapeutics Inc (DCOY) has joined the Webull Corporate Connect Service Platform, enhancing its visibility and accessibility to investors. This partnership aims to facilitate better communication and engagement with the investment community, potentially attracting more interest in the company's innovative therapeutic solutions. Joining the Webull platform may moderately enhance investor engagement and visibility, impacting market sentiment and interest in the company.

Decoy Therapeutics Inc has participated in a virtual investor segment titled 'What This Means,' focusing on its recently announced Global Access Commitment Agreement. This agreement aims to enhance access to its therapeutic solutions globally, reflecting the company's commitment to addressing healthcare disparities and improving patient outcomes. The Global Access Commitment Agreement is a significant strategic move that could enhance Decoy Therapeutics' market positioning and investor sentiment.

Decoy Therapeutics has entered into a Global Access Commitment Agreement aimed at developing a scalable peptide-conjugate manufacturing platform. This initiative focuses on ensuring global accessibility to peptide-conjugate therapies, which could enhance treatment options for patients worldwide. The agreement signifies a strategic move to address manufacturing challenges and improve the availability of these therapies in various markets. The agreement is likely to significantly impact future operations and market positioning by enhancing manufacturing capabilities and accessibility of therapies.

Salarius Pharmaceuticals, Inc. has officially changed its corporate name to Decoy Therapeutics and its Nasdaq ticker symbol to DCOY. This rebranding reflects the company's renewed focus on developing next-generation peptide conjugate therapeutics. The name change and new focus on peptide conjugate therapeutics represent a significant strategic shift that could enhance the company's market positioning and investor interest.

Salarius Pharmaceuticals, Inc. announced a planned corporate name and ticker symbol change to Decoy Therapeutics. This change reflects a strategic pivot towards developing next-generation antiviral and peptide-conjugate platforms, aiming to enhance its focus on innovative therapeutic solutions. The name and ticker change signifies a major strategic shift that could significantly alter the company's trajectory and investor sentiment.

NanOlogy has appointed David J. Arthur as Chief Executive Officer to lead the clinical development of its Large Surface Area Microparticle (LSAM) investigational drug portfolio. Arthur brings extensive experience in the pharmaceutical industry, aiming to enhance the company's strategic direction and accelerate its drug development efforts. The appointment of a new CEO with relevant experience is likely to significantly impact the company's strategic direction and clinical development efforts.

Salarius Pharmaceuticals, Inc. has announced a collaboration with the Texas Biomedical Research Institute to study avian influenza. This partnership aims to explore potential treatments and preventive measures against the virus, leveraging Salarius' expertise in drug development. The collaboration is expected to enhance research efforts in combating avian flu, which poses significant health risks to both animals and humans. The collaboration may enhance Salarius' research capabilities and market positioning but is unlikely to have an immediate transformative effect on its overall trajectory.

Salarius Pharmaceuticals, Inc. is highlighted in a market research report focusing on Ewing Sarcoma, alongside major players like Eli Lilly, Pfizer, and BioAtla. The report outlines the competitive landscape and innovations in targeted therapies for this rare cancer, projecting developments from 2025 to 2035. Salarius is positioned as a key contributor to advancements in treatment options, which may influence market dynamics and investor interest in the sector. Salarius is involved in significant innovations in targeted therapies for Ewing Sarcoma, which could notably impact its market position and investor sentiment.

Salarius Pharmaceuticals, Inc. reported its Q3 earnings, highlighting key financial metrics and operational updates. The company continues to focus on its pipeline and strategic initiatives aimed at advancing its therapeutic offerings. Investors are keenly observing the developments as they may influence future performance and market positioning. The earnings report indicates moderate changes in financial performance and operational focus that could influence investor sentiment.

Salarius Pharmaceuticals, Inc. has completed its merger with Decoy Therapeutics, a strategic move aimed at enhancing its capabilities in developing innovative cancer therapies. The merger is expected to bolster Salarius's research and development efforts, potentially leading to new treatment options and improved market positioning. The merger is a significant strategic move that could enhance Salarius's product pipeline and competitive position in the oncology market.

Salarius Pharmaceuticals, Inc. (SLRX) has been identified as one of the most active stocks in the market, indicating heightened trading activity and interest among investors. This surge in activity may reflect recent developments or investor sentiment surrounding the company's prospects. Increased trading activity suggests a moderately noticeable influence on market sentiment and potential financial performance.

Salarius Pharmaceuticals, Inc. has announced the pricing of a $7 million underwritten public offering. The offering consists of shares of common stock and warrants, with the company intending to use the proceeds for general corporate purposes, including funding clinical trials and other operational expenses. The offering is expected to close on or about a specified date, subject to customary closing conditions. The public offering may provide necessary funding for clinical trials, impacting financial performance and operational capabilities.

Salarius Pharmaceuticals, Inc. has regained compliance with all Nasdaq listing requirements, following its successful efforts to meet the necessary criteria. This achievement comes after the company faced potential delisting due to previous non-compliance issues. The company is now in good standing with Nasdaq, which is expected to positively influence investor confidence and market perception. Regaining compliance with Nasdaq listing requirements may enhance investor confidence and stabilize market perception, but it does not fundamentally alter the company's core operations.

Salarius Pharmaceuticals, Inc. has regained compliance with Nasdaq's minimum bid price requirement after its stock price rose above $1. The company had previously been notified by Nasdaq of its non-compliance but has since taken steps to address the issue. This development is seen as a positive sign for the company's market standing and investor confidence. Regaining compliance with Nasdaq's requirements can positively influence investor sentiment and market perception.

Salarius Pharmaceuticals, Inc. announced a 1-for-15 reverse stock split, aimed at increasing the per-share price of its common stock. The split is intended to help the company regain compliance with the minimum bid price requirement for continued listing on the Nasdaq. The reverse split will take effect on a date to be determined, and shareholders will receive one new share for every fifteen shares they hold. The company believes this move will enhance its marketability and attract institutional investors. The reverse stock split may improve stock price perception and compliance with listing requirements, but its overall impact on long-term performance remains limited.

Salarius Pharmaceuticals, Inc. reported its Q2 earnings, highlighting key financial metrics and operational updates. The company continues to focus on advancing its clinical programs and enhancing its financial position. Despite challenges, Salarius remains committed to its strategic goals and aims to drive growth through innovation in its product pipeline. The earnings report indicates moderate progress in financial performance and operational focus, which may influence investor sentiment and future growth.

Salarius Pharmaceuticals, Inc. (SLRX) has been identified as one of the most active stocks in the market, indicating heightened trading activity and investor interest. This surge in activity may reflect recent developments or market sentiment surrounding the company, potentially influencing its stock performance and investor engagement. Increased trading activity suggests a moderately noticeable influence on market sentiment and potential financial performance.

Salarius Pharmaceuticals, Inc. received an extension from Nasdaq to regain compliance with its stockholders' equity standard by late July 2025, following previous notifications of non-compliance. The company must also meet the minimum bid price requirement by early August 2025. Salarius is in the process of merging with Decoy Therapeutics, which focuses on peptide conjugate therapeutics. The merger aims to enhance product development and address unmet medical needs in respiratory diseases and oncology. The combined company will be led by Decoy's executive team and is expected to advance its pipeline, including a pan-coronavirus antiviral and other therapeutic candidates. The merger with Decoy Therapeutics represents a significant strategic move that could enhance Salarius' product pipeline and market position.